TickerGuard
Buy Day today: Neutral (60) Mixed market breadth · no major macro event
RGNX

Regenxbio Inc

Healthcare · Biotechnology

7.90$ -1.9% vs. previous close Closing price · As of: Sep 21, 2026

Statements

Income Statement

Regenxbio Inc (RGNX) by the numbers: income statement, balance sheet and cash flow, by year or by quarter. In the most recent period (Q2 26), "Revenue" came in at 108 million USD. Tick rows to compare them in a chart.

All figures in millions of USD.

Tick rows to compare them in a chart (up to 4)

Income Statement RGNX
Line item Q3 23 Q4 23 Q1 24 Q2 24 Q3 24 Q4 24 Q1 25 Q2 25 Q3 25 Q4 25 Q1 26 Q2 26 LTM
29 22 16 22 24 21 89 21 30 30 6.4 108 174
12 16 8.5 15 12 6.3 3.4 9.1 62 5.9 11 1.0 80
17 6.6 7.2 7.7 12 15 86 12 -32 24 -4.7 107 95
58 51 51 45 54 50 53 56 56 60 57 56 229
23 19 18 19 19 20 20 20 20 22 21 22 86
81 71 69 64 74 66 73 76 20 82 79 78 259
-65 -64 -62 -56 -62 -51 12 -63 -52 -58 -83 29 -164
1.6 1.4 2.0 0.4 0.8 9.4 8.6 11 13 12 8.7 7.8 42
-62 -63 -63 -53 -60 -51 6.1 -71 -62 -67 -90 23 -196
-2.7 -0.2 0.0
-62 -63 -63 -53 -60 -51 6.1 -71 -62 -67 -90 23 -196
-56 -57 -57 -48 -55 -38 19 -56 -45 -51 -77 34 -139

LTM = last twelve months (sum of the four most recent quarters).

Data as of: September 21, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)

Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.

Was this page helpful to you?